A phase 2, adaptive, double-blinded, placebo controlled, randomized, multicenter trial to evaluate the efficacy, safety and tolerability of intracoronary infusion of NAN-101 in adult subjects with New York Heart Association (NYHA) Class III heart failure and non-ischemic cardiomyopathy

The primary objective of this Phase 2 study is to evaluate the efficacy and safety of a single antegrade intracoronary artery infusion of NAN-101 compared to placebo infusion in subjects with non-ischemic cardiomyopathy and NYHA Class III symptoms of heart failure.

Secondary Objectives:

To evaluate the impact of NAN-101 on cardiac function, exercise capacity, quality of life (QOL), and cardiac biomarker (NT-proBNP level).